
Merck drug extends survival in stomach cancer trial
Merck reported that its experimental antibody drug conjugate sac TMT extended overall survival in patients with advanced stomach and esophageal cancers. Although it met the primary goal, the drug did not improve progression free survival.
Xurve View
Insights:
Xurve View

Merck's experimental cancer drug sac-TMT extended overall survival in advanced stomach and esophageal cancer patients during a late-stage trial on Friday morning. The study evaluated 473 patients whose disease progressed after at least two prior treatments. Investors are closely monitoring the asset's pipeline progress as Merck expands its oncology portfolio.











